AgeX Therapeutics to Present at Investing in the Age of Longevity Conference
November 08 2019 - 6:58PM
Business Wire
AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a
biotechnology company focused on developing therapeutics for human
aging and regeneration, announced today that the company will
present at Investing in the Age of Longevity, organized by Master
Investor, Ltd., on Wednesday, November 13 at Science Gallery
London.
Details of the company’s participation:
- 10:45am GMT, Science Track: A presentation on AgeX’s induced
Tissue Regeneration (iTRTM) product development by Michael D. West,
Ph.D., AgeX’s founder and CEO
- 2:55pm: Showcase Track: A presentation on AgeX’s cell therapy
approach by Nafees Malik, MD, AgeX’s Chief Operating Officer
The full event program is available here.
About AgeX Therapeutics
AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on
developing and commercializing innovative therapeutics for human
aging. Its PureStem® and UniverCyte™ manufacturing and
immunotolerance technologies are designed to work together to
generate highly-defined, universal, allogeneic, off-the-shelf
pluripotent stem cell-derived young cells of any type for
application in a variety of diseases with a high unmet medical
need. AgeX has two preclinical cell therapy programs: AGEX-VASC1
(vascular progenitor cells) for tissue ischemia and AGEX-BAT1
(brown fat cells) for Type II diabetes. AgeX’s revolutionary
longevity platform induced Tissue Regeneration (iTR™) aims to
unlock cellular immortality and regenerative capacity to reverse
age-related changes within tissues. AGEX-iTR1547 is an iTR-based
formulation in preclinical development. HyStem® is AgeX’s delivery
technology to stably engraft PureStem cell therapies in the body.
AgeX is developing its core product pipeline for use in the clinic
to extend human healthspan and is seeking opportunities to
establish licensing and collaboration agreements around its broad
IP estate and proprietary technology platforms.
For more information, please visit www.agexinc.com or connect
with the company on Twitter, LinkedIn, Facebook, and YouTube.
Forward-Looking Statements
Certain statements contained in this release are
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. Any statements that are
not historical fact including, but not limited to statements that
contain words such as “will,” “believes,” “plans,” “anticipates,”
“expects,” “estimates” should also be considered forward-looking
statements. Forward-looking statements involve risks and
uncertainties. Actual results may differ materially from the
results anticipated in these forward-looking statements and as such
should be evaluated together with the many uncertainties that
affect the business of AgeX Therapeutics, Inc. and its
subsidiaries, particularly those mentioned in the cautionary
statements found in more detail in the “Risk Factors” section of
AgeX’s Annual Report on Form 10-K and Quarterly Reports on Form
10-Q filed with the Securities and Exchange Commissions (copies of
which may be obtained at www.sec.gov). Subsequent events and
developments may cause these forward-looking statements to change.
AgeX specifically disclaims any obligation or intention to update
or revise these forward-looking statements as a result of changed
events or circumstances that occur after the date of this release,
except as required by applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191108005662/en/
Media Contact for AgeX:
Bill Douglass Gotham Communications, LLC bill@gothamcomm.com
(646) 504-0890
AgeX Therapeutics (AMEX:AGE)
Historical Stock Chart
From Aug 2024 to Sep 2024
AgeX Therapeutics (AMEX:AGE)
Historical Stock Chart
From Sep 2023 to Sep 2024